BCDA
BioCardia, Inc. NASDAQ Listed Nov 13, 1996$1.09
Mkt Cap $6.3M
52w Low $1.00
4.7% of range
52w High $2.92
50d MA $1.20
200d MA $1.43
P/E (TTM)
-0.9x
EV/EBITDA
-0.8x
P/B
8.3x
Debt/Equity
0.6x
ROE
-919.3%
P/FCF
-1.1x
RSI (14)
—
ATR (14)
—
Beta
0.55
50d MA
$1.20
200d MA
$1.43
Avg Volume
67.1K
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
320 Soquel Way · Sunnyvale, CA 94085 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | -0.20 | -0.06 | +70.0% | 1.21 | -0.8% | -0.8% | -1.7% | -1.7% | +0.0% | +4.3% | — |
| Nov 12, 2025 | AMC | -0.25 | -0.24 | +4.0% | 1.30 | -0.8% | -3.1% | -2.4% | -0.8% | +5.7% | +2.3% | — |
| Aug 11, 2025 | AMC | -0.25 | -0.40 | -60.0% | 1.68 | +0.0% | +3.6% | +6.9% | +1.6% | +1.6% | -2.1% | — |
| May 14, 2025 | AMC | -0.39 | -0.59 | -51.3% | 2.77 | -1.1% | -16.2% | +5.2% | -9.8% | -10.9% | -4.1% | — |
| Mar 26, 2025 | AMC | -0.87 | -0.25 | +71.3% | 2.55 | +3.9% | +5.1% | +4.5% | -9.3% | -15.7% | +6.1% | — |
| Nov 13, 2024 | AMC | -1.19 | -0.61 | +48.7% | 2.35 | -2.6% | -14.0% | -8.4% | +10.8% | -1.0% | -2.0% | — |
| Aug 13, 2024 | AMC | -0.10 | -0.88 | -780.0% | 2.64 | +4.2% | -1.9% | +12.0% | +14.5% | +20.5% | -16.8% | — |
| May 14, 2024 | AMC | -3.00 | -1.35 | +55.0% | 5.94 | -1.5% | +1.0% | -1.0% | -1.0% | +0.0% | +3.6% | — |
| Mar 27, 2024 | AMC | -1.65 | -1.35 | +18.2% | 6.29 | -7.0% | -2.9% | -2.8% | +1.0% | -1.7% | -2.0% | — |
| Nov 8, 2023 | AMC | -1.80 | -1.80 | +0.0% | 19.59 | -0.2% | -5.8% | -4.9% | +2.4% | -10.7% | -11.7% | — |
| Aug 9, 2023 | AMC | -2.25 | -2.55 | -13.3% | 40.89 | -2.1% | -0.4% | -1.9% | -0.3% | -0.6% | -2.0% | — |
| May 10, 2023 | AMC | -1.95 | -2.55 | -30.8% | 89.55 | +0.0% | +0.5% | -3.5% | -4.1% | -2.7% | -5.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.16 | $1.17 | +0.9% | -4.3% | +27.0% | +5.0% | -4.7% | +0.7% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.10 | $2.10 | +0.0% | -4.8% | -8.0% | +7.1% | +2.0% | -0.5% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.35 | $2.29 | -2.6% | -14.0% | -8.4% | +10.8% | -1.0% | -2.0% |
| Oct 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.42 | $2.50 | +3.3% | +8.7% | -8.0% | -2.1% | -1.7% | +2.6% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.33 | $3.33 | +0.0% | -12.9% | -6.9% | -7.8% | +11.2% | -11.2% |
| Aug 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.90 | $2.89 | -0.3% | +14.5% | +20.5% | -16.8% | -12.9% | -6.9% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.95 | $2.90 | -1.7% | +1.4% | +6.0% | -4.1% | -1.0% | -1.7% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.25 | $5.24 | -0.2% | -1.5% | +0.6% | -11.2% | -4.3% | +0.0% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.97 | $19.35 | +7.7% | -10.7% | -11.7% | -15.3% | -10.0% | -0.1% |
| Oct 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.55 | $18.33 | +4.4% | +28.2% | -13.9% | +2.2% | -4.5% | -1.6% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.10 | $24.66 | -5.5% | -12.5% | -0.7% | -8.7% | -5.2% | +0.8% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.89 | $40.02 | -2.1% | -0.4% | -1.9% | -0.3% | -0.6% | -2.0% |
| Jul 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $89.10 | $59.40 | -33.3% | -44.7% | -4.6% | -4.3% | -10.2% | +8.7% |
| Jun 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $112.05 | $116.55 | +4.0% | +12.4% | -14.6% | +7.9% | +0.4% | -0.8% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $89.55 | $89.55 | +0.0% | +0.5% | -3.5% | -4.1% | -2.7% | -5.6% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $93.15 | $90.96 | -2.4% | -6.3% | +0.5% | +2.6% | +0.0% | +0.0% |
| Nov 11 | Dawson James | Downgrade | Buy → Neutral | — | $83.70 | $83.04 | -0.8% | -0.5% | +1.1% | +0.5% | -2.1% | +1.1% |
| Dec 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $78.75 | $90.00 | +14.3% | +14.9% | +5.0% | +6.2% | +11.2% | +1.6% |
| Apr 16 | Dawson James | Downgrade | Buy → Neutral | — | $185.40 | $182.25 | -1.7% | -3.4% | -8.8% | -3.9% | +5.4% | +0.0% |
| Nov 25 | Maxim Group | Maintains | Buy → Buy | — | $101.70 | $103.50 | +1.8% | +4.9% | -0.8% | +0.0% | +5.1% | -1.2% |
| Nov 25 | Brookline Capital | Maintains | Buy → Buy | — | $101.70 | $103.50 | +1.8% | +4.9% | -0.8% | +0.0% | +5.1% | -1.2% |
| Nov 25 | Alliance Global Partners | Maintains | Buy → Buy | — | $101.70 | $103.50 | +1.8% | +4.9% | -0.8% | +0.0% | +5.1% | -1.2% |
| Sep 21 | Alliance Global Partners | Maintains | Buy → Buy | — | $110.25 | $114.30 | +3.7% | +6.5% | -5.4% | -2.4% | -0.4% | -1.2% |
| Nov 26 | Brookline Capital | Maintains | Buy → Buy | — | $157.95 | $158.49 | +0.3% | +31.6% | -1.6% | +1.2% | +1.3% | +3.0% |
| Oct 10 | Maxim Group | Maintains | Buy → Buy | — | $151.20 | $157.35 | +4.1% | +4.0% | +1.7% | +3.3% | +1.2% | +14.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | Altman PeterDir/Off | President and CEO | Buy | 5,000 | $1.11 | $6K | 280,766 | +3.64% | +0.91% |
8-K · 7.01
! Medium
BioCardia, Inc. -- 8-K 7.01: Regulation FD Disclosure
BioCardia's Helix catheter system received FDA validation of two regulatory pathways forward with no safety concerns raised, positioning the company to advance toward market clearance.
May 8
8-K · 8.01
!! High
BioCardia, Inc. -- 8-K 8.01: Material Event / Announcement
BioCardia received a patent for its Heart3D Fusion Imaging software, strengthening intellectual property protection for its CardiAMP Cell Therapy treatment planning and navigation technology.
Apr 28
8-K · 7.01
! Medium
BioCardia, Inc. -- 8-K 7.01: Regulation FD Disclosure
BioCardia's CardiAMP Cell Therapy received positive feedback from Japan's PMDA, indicating clinical evidence likely supports market approval for ischemic heart failure treatment, potentially opening a major international market.
Apr 20
8-K
Unknown — 8-K Filing
BCDA faces potential Nasdaq delisting due to non-compliance with listing standards; investors should monitor whether management's remediation plan succeeds, as delisting would severely damage liquidity and valuation.
Apr 15
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
BCDA's FDA submission of positive CardiAMP HF data and pursuit of accelerated approval could enable faster market entry and revenue generation, significantly reducing development timeline risk for investors.
Apr 2
8-K
Unknown — 8-K Filing
BioCardia's 2025 annual results filing likely signals operational progress in cardiovascular therapeutics development, but investors should scrutinize cash burn rates and runway given biotech sector funding challenges.
Mar 24
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
BioCardia's FDA pre-submission approval package acceptance and scheduled Q2 review meeting reduces regulatory uncertainty for its Helix catheter, potentially enabling faster commercialization and revenue generation for this cardiovascular device.
Mar 17
8-K · 7.01
! Medium
BioCardia, Inc. -- 8-K 7.01: Regulation FD Disclosure
BioCardia's Phase III CardiAMP HF trial showed positive late-breaking echocardiography results for ischemic heart failure treatment, potentially supporting future regulatory approval and market commercialization prospects.
Mar 3
8-K · 8.01
!! High
BioCardia, Inc. -- 8-K 8.01: Material Event / Announcement
BioCardia completed FDA pre-submission review for its Helix catheter, positioning the company to advance toward formal approval processes for its intramyocardial delivery device.
Feb 10
8-K · 8.01
!! High
BioCardia, Inc. -- 8-K 8.01: Material Event / Announcement
BioCardia's CardiAMP cell therapy heart failure data will be presented at a prestigious March 2026 conference, potentially validating its clinical progress and supporting future commercialization prospects.
Feb 3
Data updated apr 24, 2026 8:52pm
· Source: massive.com